Amicus Therapeutics Inc. [NASDAQ: FOLD] plunged by -$0.58 during the normal trading session on Thursday and reaching a high of $22.75 during the day while it closed the day at $21.72. The company report on November 5, 2020 that Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates.
Galafold 3Q20 Revenue of $67.4 Million, On-Track to Achieve Revenue Guidance of $250M-$260M.
AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20.
Amicus Therapeutics Inc. stock has also loss -0.37% of its value over the past 7 days. However, FOLD stock has inclined by 48.77% in the 3 months of the year. Over the past six months meanwhile, it has gained 71.29% and gained 123.00% year-on date.
The market cap for FOLD stock reached $5.61 billion, with 259.16 million shares outstanding and 233.87 million shares in the current float. Compared to the average trading volume of 1.91M shares, FOLD reached a trading volume of 2085262 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc. [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $21.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Berenberg have made an estimate for Amicus Therapeutics Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 11, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on June 17, 2020, representing the official price target for Amicus Therapeutics Inc. stock. Previously, the target price had yet another raise from $19 to $20, while Cantor Fitzgerald kept a Overweight rating on FOLD stock. On November 12, 2019, analysts increased their price target for FOLD shares from 18 to 20.
The Average True Range (ATR) for Amicus Therapeutics Inc. is set at 1.08, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 22.86. The Price to Book ratio for the last quarter was 17.52, with the Price to Cash per share for the same quarter was set at 1.97.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc. [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.37. With this latest performance, FOLD shares gained by 23.13% in over the last four-week period, additionally plugging by 71.29% over the last 6 months – not to mention a rise of 126.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 66.32, with the RSI for the last a single of trading hit 60.98, and the three-weeks RSI is set at 66.20 for Amicus Therapeutics Inc. [FOLD]. The present Moving Average for the last 50 days of trading for this stock 17.10, while it was recorded at 22.26 for the last single week of trading, and 13.56 for the last 200 days.
Amicus Therapeutics Inc. [FOLD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc. [FOLD] shares currently have an operating margin of -165.03 and a Gross Margin at +85.33. Amicus Therapeutics Inc.’s Net Margin is presently recorded at -195.56.
Return on Total Capital for FOLD is now -44.51, given the latest momentum, and Return on Invested Capital for the company is -53.03. Return on Equity for this stock declined to -86.99, with Return on Assets sitting at -43.46. When it comes to the capital structure of this company, Amicus Therapeutics Inc. [FOLD] has a Total Debt to Total Equity ratio set at 44.13. Additionally, FOLD Total Debt to Total Capital is recorded at 30.62, with Total Debt to Total Assets ending up at 24.73. Long-Term Debt to Equity for the company is recorded at 42.62, with the Long-Term Debt to Total Capital now at 29.57.
Reflecting on the efficiency of the workforce at the company, Amicus Therapeutics Inc. [FOLD] managed to generate an average of -$610,253 per employee. Receivables Turnover for the company is 6.60 with a Total Asset Turnover recorded at a value of 0.22.Amicus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.10 and a Current Ratio set at 5.20.
Earnings per share (EPS) analysis for Amicus Therapeutics Inc. [FOLD] stock
With the latest financial reports released by the company, Amicus Therapeutics Inc. posted -0.35/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -29.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amicus Therapeutics Inc. go to -1.00%.
Amicus Therapeutics Inc. [FOLD]: Insider Ownership positions
There are presently around $6,052 million, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: PERCEPTIVE ADVISORS LLC with ownership of 25,122,048, which is approximately -0.24% of the company’s market cap and around 1.10% of the total institutional ownership; VANGUARD GROUP INC, holding 23,187,567 shares of the stock with an approximate value of $503.63 million in FOLD stocks shares; and REDMILE GROUP, LLC, currently with $501.21 million in FOLD stock with ownership of nearly -7.492% of the company’s market capitalization.
Positions in Amicus Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 122 institutional holders increased their position in Amicus Therapeutics Inc. [NASDAQ:FOLD] by around 18,454,426 shares. Additionally, 113 investors decreased positions by around 20,822,486 shares, while 34 investors held positions by with 239,338,157 shares. The mentioned changes placed institutional holdings at 278,615,069 shares, according to the latest SEC report filing. FOLD stock had 42 new institutional investments in for a total of 4,448,359 shares, while 20 institutional investors sold positions of 4,150,475 shares during the same period.